Physiological basis of insulin secretion abnormalities;Les bases physiologiques des troubles de l'insulinosécrétion

Diabetes and Metabolism

Volumn 28, Issue 6 SUPPL., 2002, Pages

  Pinget, M ^a   Boullu Sanchis, S ^a  

^a HÔPITAL CIVIL   (France)

Author keywords

Genetics; Insulin secretion; Lipotoxicity; Transcription factors; Type 2 diabetes

Indexed keywords

INSULIN;

APOPTOSIS; CONFERENCE PAPER; HUMAN; HUMAN CELL; HYPERGLYCEMIA; INSULIN DEFICIENCY; INSULIN RELEASE; INSULIN RESISTANCE; MATURITY ONSET DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL;

ANIMALS; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN; MITOCHONDRIA; REFERENCE VALUES;

EID: 0036997604     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (55)

1. King H, Aubert RE, Herman WH. Global burden of diabetes:1995-2025. Prevalence, numerical estimates and projections.Diabetes Care, 1998, 21, 1414-1431.
2. Medici F, Hawa M, Ianari A, Pyke DA, Leslie RD. Concordance rate for type II diabetes mellitus in monozygotic twins: actuarial analysis. Diabetologia, 1999, 42, 146-150.
3. Expert Commitee on the diagnosis and classification of diabetes mellitus. Diabetes Care, 1997, 20, 1183-1197.
4. Hattersley AT. Maturity onset diabetes of the young: clinical heterogeneity explained by genetic heterogeneity. Diabet Med, 1998, 15, 15-24.
5. Yamagata K, Furuta K, Oda N, et al. Mutations in the hepatocyte nuclear factor-4α gene in maturity-onset diabetes of the young (MODY 1). Nature, 1996, 384, 458-460.
6. Froguel P, Zouali H, Vionnet N, et al. Familial hyperglycemia due to mutations in glucokinase: definition of a subtype of diabetes mellitus. N Engl J Med, 1993, 328, 697-702.
7. Permutt MA, Hattersley AT. Searching for type 2 diabetes genes in the postgenome era. Trends Endocrinol Metab, 2000, 11, 383-393.
8. Ellard S, Beards F, Allen LI, et al. A high prevalence of glucokinase mutations in diabetic subjects selected by clinical criteria. Diabetologia, 2000, 43, 250-253.
9. Hattersley AT, Beards F, Ballantyne E, Appleton M, Harvey R, Ellard S. Mutations in the glucokinase gene of the fetus results in reduced birth weight. Nat Genet, 1998, 19, 268-270.
10. Prisco F, Iafusco D, Franzese A, Sulli N, Barnetti F. MODY 2 presenting as neonatal hyperglycemia: a need to reshape the definition of neonatal diabetes. Diabetologia, 2000, 43, 1331-1332.
11. Vaxillaire M, Boccio V, Philippi A, et al. A gene for maturity-onset diabetes of the young (MODY) maps to chromosome 12q. Nat Genet, 1995, 9, 418-423.
12. Cox RD, Southam L, Hashim Y, et al. UKPDS 31: Hepatocyte nuclear factor-1 alpha (the MODY 3) mutations in late onset type II diabetic patients in the United-Kingdom. United-Kingdom prospective diabetes study. Diabetologia, 1999, 42, 120-121.
13. Lehto M, Tuomi T, Mahtani MM, et al. Characterization of the MODY 3 phenotype. J Clin Invest, 1997, 99, 582-591.
14. Pearson ER, Liddell WG, Shepherd M, Corrall RJ, Hattersley AT. Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor-1α gene mutations: evidence for pharmacogenetics in diabetes. Diabet Med, 2000, 17, 543-545.
15. Stoffers DA, Zinkin NT, Stanojevic V, Clarke WL, Habener JF. Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF-1 gene coding sequence. Nat Genet, 1997, 15, 106-110.
16. Hani EH, Stoffers DA, Chèvre JC, et al. Defective mutations in the insulin promoter factor-1 (IPF-1) gene in late-onset type 2 diabetes mellitus. J Clin Invest, 1999, 104, R41-R48.
17. Bingham C, Ellard S, Allen LI, et al. Abnormal nephron development associated with a framshift mutation in the transcription factor hepatocyte nuclear factor-1beta. Kidney Int, 2000, 57, 898-907.
18. Malecki MT, Jhala US, Antonellis A, et al Mutations in NeuroD1 are associated with the development of type 2 diabetes mellitus. Nat Genet, 1999, 23, 323-328.
19. van den Ouweland JMW, Lemkes HHPJ, Ruittenbeek W, et al. Mutation in mitochondrial tRNALeu(UUR) gene in a large pedigree with maternally transmitted type II diabetes mellitus and deafness. Nat Genet, 1992, 1, 368-371.
20. Guillausseau PJ, Massin P, Dubois-Laforgue D, et al. Maternally inherited diabetes and deafness: a multicenter study. Ann Intern Med, 2001, 134, 721-728.
21. Hanis CL, Boerwinkle E, Chakraborty R, et al. A genome-wide search for human non-insulin-dependent (type 2) diabetes genes reveals a major susceptibility locus on chromosome 2. Nat Genet, 1996, 13, 161-166.
22. Horikawa Y, Oda N, Cox NJ, et al. Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet, 2000, 26, 163-175.
23. Baier LJ, Paskasari AP, Yang X, et al. A calpain-10 gene polymorphism is associated with reduced muscle mRNA levels and insulin resistance. J Clin Invest, 2000, 106, R69-R73.
24. Vionnet N, Hani EH, Dupont S, et al. Genome-wide search for type 2 diabetes-susceptibility genes in French Whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-ter and independent replication of a type 2-diabetes locus on chromosome Iq21-q24. Am J Genet, 2000, 67, 1470-1480.
25. McGarry JD, Dobbins RL. Fatty acids, lipotoxicity and insulin secretion. Diabetologia, 1999, 42, 128-138.
26. Girard J. Rôle des acides gras libres dans l'insulinorésistance au cours du diabète non insulinodépendant. Diabetes Metab, 1995, 21, 79-88.
27. Berne C. The metabolism of lipids in mouse pancreatic islets: the oxidation of fatty acids and ketone bodies. Biochem J, 1975, 152, 661-666.
28. Malaisse WJ, Malaisse-Lagae F, Sener A, Hellerström C. Participation of endogenous fatty acids in the secretory activity of the pancreatic β-cell. Biochem J, 1995, 227, 995-1002.
29. Zierler KL. Fatty acids as substrates for heart and skeletal muscle. Circulation Res, 1976, 39, 459-463.
30. Paolisso G, Gambardella A, Amato L, et al. Opposite effects of short-and long-term fatty acid infusion on insulin secretion in healthy subjects. Diabetologia, 1995, 38, 1295-1299.
31. Boden G, Chen XH, Rosner J, Barton M. Effects of a 48-h fat infusion on insulin secretion and glucose utilization. Diabetes, 1995, 44, 1239-1242.
32. Dobbins RL, Chester MW, Daniels MB, McGarry JD, Stein DT. Circulating fatty acids are essential for efficient glucose-stimulated insulin secretion after prolonged fasting in humans. Diabetes, 1998, 47, 1613-1618.
33. Chalkley SM, Kraegen EW, Furler SM, Campbell LV, Chisholm DJ. NEFA elevation during a hyperglycaemic clamp enhances insulin secretion. Diabet Med, 1998, 15, 327-333.
34. Carpentier A, Mittelman SD, Bergman RN, Giacca A, Lewis GF. Acute enhancement of insulin secretion by FFA in humans is lost with prolonged FFA elevation. Am J Physiol, 1999, 276, E1055-E1066.
35. Sako Y, Gril V. A 48-hour lipid infusion in the rat time-dependently inhibits glucose-induced insulin secretion and β-cell oxidation through a process likely coupled to fatty acid oxidation. Endocrinol, 1990, 127, 1580-1589.
36. Mason TM, Goh T, Tchipashvili, et al. Prolonged elevation of plasma free fatty acids desensitizes the insulin secretory response to glucose in vivo in rats. Diabetes, 1999, 48, 524-530.
37. Stein DT, Stevenson BE, Chester MW et al. The insulinotropic potency of fatty acids is profoundly influenced by their chain length and degree of saturation. J Clin Invest, 1997, 100, 398-403.
38. Liang Y, Buettger C, Berner DK, Matschinsky FM. Chronic effect of fatty acids on insulin release is not through the alteration of glucose metabolism in a pancreatic β-cell line (βHC9). Diabetologia, 1997, 40, 1018-1027.
39. Zhou YP, Grill VE. Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle. J Clin Invest, 1994, 93, 870-876.
40. Segall L, Lameloise N, Assmacopoulos-Jeannet F, et al. Lipid rather than glucose metabolism is implicated in altered insulin secretion caused by oleate in INS-1 cells. Am J Physiol, 1999, 277, E521-E528.
41. Tokuyama Y, Sturis J, DePaoli AM, et al. Evolution of β-cell dysfunction in the male Zucker diabetic fatty rat. Diabetes, 1995, 44, 1447-1457.
42. Pick A, Clark J, Kabstrup C, et al. Role of apoptosis in failure of β-cell mass compensation for insulin resistance and β-cell defects in the male Zucker diabetic fatty rat. Diabetes, 1998, 47, 358-364.
43. Man ZW, Zhu M, Noma Y, et al. Impaired β-cell function and deposition of fat droplets in the pancreas as a consequence of hypertriglyceridemia in OLETF rat, a model of spontaneous NIDDM. Diabetes, 1997, 46, 1718-1724.
44. Lee Y, Hirose H, Ohneda M, Johnson J, McGarry J, Unger R. β-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-β-cell relationships. Proc Natl Acad Sci USA, 1994, 91, 10878-10882.
45. Lee Y, Hirose H, Zhou YT, Esser V, McGarry JD, Unger RH. Increased lipogenic capacity of the islets of obese rats: a role in the pathogenesis of NIDDM. Diabetes, 1997, 46, 408-413.
46. Shimabukuro M, Zhou YT, Levi M, Unger RH. Fatty acid-induced cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci USA, 1998, 95, 2498-2502.
47. Johnson JH, Ogawa A, Chen L, et al. Underexpression of β-cell high Km glucose transporters in noninsulin-dependent diabetes. Science, 1990, 250, 546-549.
48. Shimabukuro M, Ohneda M, Lee Y, Unger RH. Role of Nitric Oxide in obesity-induced β-cell disease. J Clin Invest, 1997, 100, 290-295.
49. Shimabukuro M, Wang MY, Zhou YT, Newgard CB, Unger RH. Protection against lipoapoptosis of β-cells through leptin-dependent maintenance of Bcl-2 expression. Proc Natl Acad Sci USA, 1998, 95, 9558-9561.
50. Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM: Genetic and clinical implications. Diabetes, 1995, 44, 863-870.
51. Unger RH. How obesity causes diabetes in Zucker diabetic fatty rat. Trends Endocrinol Metab, 1997, 8, 276-282.
52. Shimabukuro M, Higa M, Zhou YT, Wang MY, Newgard CB, Unger RH. Lipoapoptosis in β-cells of obese prediabetic fa/fa rats. Role of serine palmitoyl-transferase overexpression. J Biol Chem, 1998, 273, 32487-32490.
53. Ohneda M, Inman LR, Unger RH. Caloric restriction in obese pre-diabetic rats prevents β-cell depletion, loss of β-cell GLUT2 and glucose incompetence. Diabetologia, 1995, 38, 173-179.
54. Wang MY, Koyama K, Shimabukuro M, Newgard CB, Unger RH. OB-Rb gene transfer to leptin-resistant islets reverses diabetogenic phenotype. Proc Natl Acad Sci USA, 1998, 95, 714-718.
55. Higa M, Zhou YT, Ravazzola M, Baetens D, Orci L, Unger RH. Troglitazone prevents mitochondrial alterations, β-cell destruction, and diabetes in obese prediabetic rats. Proc Natl Acad Sci USA, 1999, 96, 11513-11518.